HPV16 E6 TCR T Cells for Cervical Carcinoma
A Phase I/II Clinical Trail of TC-E202 Targeting HPV16 E6 for Relapsed/Refractory to Standard Treatment or Metastatic Cervical Carcinoma
Sponsor: Fudan University
Terminated
Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs
Other terminated trials from Fudan University
Other Cervical Carcinoma trials with similar outcome
Listed as NCT05357027, this PHASE1/PHASE2 trial focuses on Cervical Carcinoma and remains terminated or withdrawn. Sponsored by Fudan University, it has been updated 7 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Nov 2022 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
- TCRCure Biopharma Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .